Lipid changes in atherosclerotic aortas of Macaca fascicularis after various regression regimens.
plasma and aortic tissue lipid changes in atherosclerotic Macaca fascicularis monkeys were studied following various regression regimens for 18 months. Atherosclerosis was induced in groups of 18 Macaca fascicularis monkeys by feeding a semipurified diet containing 43% of the calories as fat and 1.2 mg/kcal cholesterol for 6 months. Five groups of animals were continued on the same diet containing 0.34 mg/kcal cholesterol during the regression period, and were given the following hypocholesterolemic regimens: none (positive controls); D-thyroxine; pyrimidine derivative; cholestyramine; and alfalfa. Another group of animals was maintained on regular monkey chow alone during the regression period (negative control). Among the hypocholesterolemic agents, cholestyramine very effectively reduced the plasma cholesterol, and aorta free- and esterified cholesterol and phospholipids. D-Thyroxine significantly lowered the plasma cholesterol levels but, surprisingly, tissue lipid levels were the highest among the groups studied. Alfalfa, although not as effective as cholestyramine, tended to reduce the plasma and tissue lipids more than other drugs. Pyrimidine derivative actually increased the mean levels of plasma and tissue cholesterol. Plasma cholesterol correlated positively with aortic tissue cholesterol, free and esterified cholesterol. Both the plasma percentage distribution of alpha-lipoprotein and the phospholipid/cholesterol ratio were inversely related to all tissues lipids. Plasma cholesterol accounted for 43% and 30% respectively of the variability in tissue total and esterified cholesterol. Thus the effectiveness of any hypocholesterolemic regimen is probably dependent on achieving a favorable lipoprotein distribution in plasma without any adverse effect on the arterial wall metabolism.
D000818:Animals; D001011:Aorta / Q000378:metabolism*; D001161:Arteriosclerosis / Q000097:blood / Q000188:drug therapy / Q000378:metabolism*; D002784:Cholesterol / Q000378:metabolism; D002792:Cholestyramine Resin / Q000627:therapeutic use; D003918:Dextrothyroxine / Q000627:therapeutic use; D005260:Female; D050356:Lipid Metabolism; D008055:Lipids / Q000097:blood; D008252:Macaca fascicularis; D000455:Medicago sativa; D010743:Phospholipids / Q000378:metabolism; D011743:Pyrimidines / Q000627:therapeutic use
D008055:Lipids; D010743:Phospholipids; D011743:Pyrimidines; D002792:Cholestyramine Resin; D003918:Dextrothyroxine; C006253:pirinixic acid; D002784:Cholesterol